Show Summary Details
Page of

Haemostasis management 

Haemostasis management
Haemostasis management

David Royston

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 October 2020

Various laboratory and point-of-care (POC) tests that can be used to guide blood component therapy in order to optimize haemostasis and coagulation are described. The aim of this effort is to minimize bleeding associated with surgery and trauma. In addition to a discussion of the various viscoelastic POC tests of coagulation in whole blood the various commercially available tests of whole blood coagulation used to guide therapy with unfractionated heparin during extracorporeal circulation are compared. The various pharmacological agents that have been and are used to promote haemostasis and reduce bleeding are discussed. Following a brief discussion of drugs acting primarily on platelet functions (such as epoprostenol and DDAVP/desmopressin) drugs that are considered to act on the fibrinolytic system are compared, as well as safety aspects: in particular, the safety concerns and current recommendations on aprotinin use.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.